Compare AVAV & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVAV | ABVX |
|---|---|---|
| Founded | 1971 | 2013 |
| Country | United States | France |
| Employees | N/A | 69 |
| Industry | Aerospace | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 7.2B |
| IPO Year | 2006 | N/A |
| Metric | AVAV | ABVX |
|---|---|---|
| Price | $138.20 | $97.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $316.88 | $131.31 |
| AVG Volume (30 Days) | 1.3M | ★ 2.8M |
| Earning Date | 03-10-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $135.55 | $52.14 |
| Revenue Next Year | $14.90 | $4,132.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $135.20 | $7.41 |
| 52 Week High | $417.86 | $148.83 |
| Indicator | AVAV | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 43.75 |
| Support Level | N/A | $87.60 |
| Resistance Level | $220.08 | $98.59 |
| Average True Range (ATR) | 8.96 | 7.37 |
| MACD | -4.51 | -0.07 |
| Stochastic Oscillator | 6.83 | 71.13 |
AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.